Medicare AdvantageBilling CodesHigh impact
MA08.007as, Medicare Part B vs. Part D Crossover Drugs
Independence Blue Cross·Pharmacy·Pharmacy
Effective date
Sep 22, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.007as clarifies the distinction between Medicare Part B and Part D coverage for crossover drugs. This policy establishes billing rules for medications that can be covered under either Part B (medical benefits) or Part D (pharmacy benefits) depending on the clinical context and administration method. Billing teams must ensure claims are submitted to the correct part to avoid denials and ensure proper reimbursement.
Action Required
By September 22, 2025: Billing team must review the complete MA08.007as policy to identify all crossover drugs affecting your practice. Update billing system logic and encounter forms to route these drug claims to either Part B or Part D based on administration method and clinical context as specified in the policy. Pharmacy staff and providers must document whether each drug administration qualifies for Part B (e.g., provider-administered injections) versus Part D (e.g., patient self-administered medications). Train all billing and clinical staff on the Part B vs. Part D determination criteria. Test claims submission workflow before the effective date. Failure to apply correct Part B/D routing will result in claim denials and payment delays. Contact the plan for a detailed drug-by-drug crossover list if not provided in the full policy text.